- Home
- / Nanexa
Nanexa
Revenue
KR36.1 M
FY, 2025
Nanexa Summary
Company Summary
- Overview
- Nanexa is a company that specializes in drug delivery nanotechnologies. It provides the PharmaShell drug delivery system that can be used with a number of substance types and indication areas. The company also develops NEX-18, a product aiming to target myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).
- Type
- Public
- Status
- Active
- Founded
- 2006
- HQ
- Uppsala, SE | view all locations
- Website
- https://www.nanexa.com/
- Cybersecurity rating
Table of Contents
Key People
Hans Arwidsson, Chairman of the Board
Bengt Gustavsson, Board Member
Magnus Westgren, Board Member
LocationsView all
1 location detected
Uppsala, Uppsala län HQ
Sweden
Virdings allé 32A
Nanexa Financials
Summary Financials
- Revenue (FY, 2025)
- kr36.1M
- Gross profit (FY, 2025)
- kr29.8M
- Net income (FY, 2025)
- (kr11.4M)
- Cash (FY, 2025)
- kr44.6M
- EBIT (FY, 2025)
- (kr8.1M)